Advertisement
Advertisement
AMGN
Amgen Inc
366.20
USDSponsored
+27.67
+8.17%
Feb 04, 16:00 UTC -5
Closed
Pre-Market
366.71
+0.51
+0.14%
AMGN Earnings Reports
Positive Surprise Ratio
AMGN beat 36 of 40 last estimates.
90%
Next Report
Date of Next Report
Apr 29, 2026
Estimate for Q1 26 (Revenue/ EPS)
$8.81B
/$5.18
Implied change from Q4 25 (Revenue/ EPS)
-10.75%
/-2.08%
Implied change from Q1 25 (Revenue/ EPS)
+8.06%
/+5.71%
Amgen Inc earnings per share and revenue
On Feb 03, 2026, AMGN reported earnings of 5.29 USD per share (EPS) for Q4 25, beating the estimate of 4.82 USD, resulting in a 9.56% surprise. Revenue reached 9.87 billion, compared to an expected 9.66 billion, with a 2.12% difference. The market reacted with a +8.15% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 13 analysts forecast an EPS of 5.18 USD, with revenue projected to reach 8.81 billion USD, implying an decrease of -2.08% EPS, and decrease of -10.75% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Bristol-Myers Squibb Co.
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.12
Actual
$1.26
Surprise
+11.88%
GSK plc - ADR
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.23
Actual
$0.49
Surprise
+111.36%
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.82
Actual
$11.44
Surprise
+5.65%
QIAGEN N.V.
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.64
Actual
$0.62
Surprise
-3.32%
Bio-Techne Corp.
Report Date
Feb 04, 2026 For Q2 26
Estimate
$0.44
Actual
$0.46
Surprise
+3.95%
Twist Bioscience Corporation Common Stock
Report Date
Feb 02, 2026 For Q1 26
Estimate
-$0.43
Actual
-$0.50
Surprise
-14.00%
Mesoblast Limited - ADR
Report Date
Jan 29, 2026 For Q1 26
Estimate
-$0.06
Actual
-$0.07
Surprise
-5.90%
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
AYTU BioPharma, Inc. Common Stock
Report Date
Feb 03, 2026 For Q2 26
Estimate
-$0.61
Actual
-$1.05
Surprise
-71.57%
FAQ
What were Amgen Inc's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Amgen Inc reported EPS of $5.29, beating estimates by 9.56%, and revenue of $9.87B, 2.12% above expectations.
How did the market react to Amgen Inc's Q4 2025 earnings?
The stock price moved up 8.15%, changed from $338.59 before the earnings release to $366.20 the day after.
When is Amgen Inc expected to report next?
The next earning report is scheduled for Apr 29, 2026.
What are the forecasts for Amgen Inc's next earnings report?
Based on 13
analysts, Amgen Inc is expected to report EPS of $5.18 and revenue of $8.81B for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement